Arrowhead Pharmaceuticals Teases Q3 Data Wave: SHASTA-3/4, RNAi Dimer and ARO-MAPT Readouts Ahead [Yahoo! Finance]
Arrowhead Pharmaceuticals, Inc. (ARWR)
Last arrowhead pharmaceuticals, inc. earnings: 2/5 04:00 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.arrowheadpharma.com/investor-relations
Company Research
Source: Yahoo! Finance
Arrowhead Pharmaceuticals (NASDAQ:ARWR) outlined a slate of expected clinical data updates during a discussion at the Leerink Partners Global Healthcare Conference in Miami, with management pointing to multiple readouts concentrated in the third quarter and additional updates expected in the second half of the year. Multiple clinical catalysts expected in the third quarter Chief Executive Officer Chris Anzalone said the company expects topline results in the third quarter from SHASTA-3 and SHASTA-4, its Phase 3 studies of plozasiran in the severe hypertriglyceridemia (SHTG) population. He noted the last patient, last visit is scheduled for June, with topline data planned for the third quarter. ? Will the Super Mario Movie Make It Showtime for Nintendo Stock? Arrowhead also expects initial data in the third quarter from its first “dimer” (bispecific) RNAi program, a single RNA molecule designed to reduce expression of both PCSK9 and APOC3 for mixed hyperlipidemia. The company
Show less
Read more
Impact Snapshot
Event Time:
ARWR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ARWR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ARWR alerts
High impacting Arrowhead Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
ARWR
News
- Arrowhead Pharmaceuticals Inc. (ARWR): Billionaire Ken Fisher Bets Big on Pharma [Yahoo! Finance]Yahoo! Finance
- Arrowhead (ARWR) FQ1 2026 Revenue Hits $264M as REDEMPLO Approval Marks Commercial Shift [Yahoo! Finance]Yahoo! Finance
- ClearBridge Small Cap Growth Portfolios Q4 2025 Commentary [Seeking Alpha]Seeking Alpha
- Arrowhead Pharmaceuticals Teases 2026 Catalysts, Waylivra Launch Momentum at TD Cowen Conference [Yahoo! Finance]Yahoo! Finance
- Assessing Arrowhead Pharmaceuticals (ARWR) Valuation After A Cooling Share Price And Strong Long-Term Returns [Yahoo! Finance]Yahoo! Finance
ARWR
Earnings
- 2/5/26 - Miss
ARWR
Sec Filings
- 3/9/26 - Form 4
- 3/5/26 - Form 144
- 2/5/26 - Form 10-Q
- ARWR's page on the SEC website